Please assess the completion status of the following clinical trial:

Trial Title: Targeting Pathways in Polycystic Ovary Syndrome (PCOS) Using Metformin (MET)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Body mass index (BMI) greater than or equal to 25~* Polycystic Ovary Syndrome criteria of both oligomenorrhea (\<9 menses per year) and androgen excess \[clinical hirsutism (Ferriman-Gallway score \>8 or severe acne) or elevated testosterone\].~* Taking no medications for the treatment of insulin resistance.~Exclusion Criteria:~* Diagnosis of Cushing's syndrome~* Untreated hypo/hyperthyroidism~* Elevated prolactin~* Congenital adrenal hyperplasia~* Renal insufficiency (creatinine \> 1.5)~* Diabetes~* Medications that can significantly affect endothelial function~* Pregnancy~* Breast Feeding~* Taking oral contraceptives~* Currently smoking

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Study Arms:
- Metformin (Type: EXPERIMENTAL): Metformin 500 mg. extended release (taken orally) one tablet with evening meal for one week, one tablet with morning and evening meal for one week, and one tablet at all three meals for the next three months.
- Delayed Start Metformin (Type: OTHER): After baseline study visit, this arm will return after three months without metformin for a repeat of the baseline study visit prior to initiating metformin 500 mg. extended release (taken orally) one tablet with evening meal for one week, one tablet with morning and evening meal for one week, and one tablet at all three meals for the next three months.

Based on this trial design, predict the completion outcome and termination type (if applicable).